The prostate cancer conundrum revisited
Cancer,  Clinical Article

Etzioni R et al. – Changes in primary treatment explained a minority of the observed decline in prostate cancer mortality. The remainder of the decline probably was because of other interventions, such as prostate–specific antigen screening and advances in the treatment of recurrent and progressive disease.

Methods
  • The authors applied 3 independently developed models of prostate cancer natural history and disease detection under common assumptions about treatment patterns, treatment efficacy, and survival in the population.
  • Primary treatment patterns were derived from the Surveillance, Epidemiology, and End Results registry; data on the frequency of hormone therapy were obtained from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) database; and treatment efficacy was based on estimates from randomized trials and comparative effectiveness studies of treatment alternatives.
  • The models projected prostate cancer mortality without prostate-specific antigen screening and in the presence and absence of treatment benefit.
  • The impact of primary treatment was expressed as a fraction of the difference between observed mortality and projected mortality in the absence of treatment benefit.

Results
  • The 3 models projected that changes in treatment explained 22% to 33% of the mortality decline by 2005.
  • These contributions were accounted for mostly by surgery and radiation therapy, which increased in frequency until the 1990s, whereas hormone therapies contributed little to the mortality decline by 2005.
  • Assuming that treatment benefit was less for older men, changes in treatment explained only 16% to 23% of the mortality decline by 2005.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Urology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Urology Articles

1 The use of metformin in patients with prostate cancer and the risk of death Cancer Epidemiology, Biomarkers & Prevention, September 22, 2014    Clinical Article

2 Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: A systematic review with meta-analyses Clinical Oncology, August 8, 2014    Evidence Based Medicine    Review Article

3 The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml Cancer Epidemiology, September 26, 2014    Clinical Article

4 Controversies associated with the evaluation of elderly men with localized prostate cancer when considering radical prostatectomy International Journal of Clinical Oncology, September 5, 2014    Clinical Article

5 An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study Prostate Cancer & Prostatic Diseases, September 15, 2014    Clinical Article

6 Proportion of tadalafil-treated patients with clinically meaningful improvement in lower urinary tract symptoms associated with benign prostatic hyperplasia - integrated data from 1499 study participants BJU International, September 12, 2014    Clinical Article

7 Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): An open-label, randomised, phase 3 factorial trial The Lancet Oncology, September 4, 2014    Clinical Article

8 Metformin in chemotherapy-naive castration-resistant prostate cancer: A multicenter phase 2 trial (SAKK 08/09) Full Text European Urology, September 3, 2014    Free full text    Clinical Article

9 An investigation into the relationship between Statins and Cancer using population-based data BJU International, September 23, 2014    Clinical Article

10 Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: Results from the randomised, phase 3 AFFIRM trial The Lancet Oncology, September 8, 2014    Clinical Article

11 Smoking and risk of low- and high-grade prostate cancer: Results from the REDUCE study Clinical Cancer Research, September 19, 2014    Clinical Article

12 Enclomiphene citrate stimulates testosterone production while preventing oligospermia: A randomized phase II clinical trial comparing topical testosterone Fertility and Sterility, July 25, 2014    Clinical Article

13 Anxiety in the management of localised prostate cancer by active surveillance BJU International, August 13, 2014    Clinical Article

14 The length of a positive surgical margin is of prognostic significance in patients with clinically localized prostate cancer treated with radical prostatectomy Urologia Internationalis, August 29, 2014    Clinical Article

15 External beam radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer Radiotherapy & Oncology, September 2, 2014    Clinical Article

16 Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients Urologic Oncology: Seminars and Original Investigations, August 20, 2014    Clinical Article

17 Evidence for molecular differences in prostate cancer between African American and Caucasian men Clinical Cancer Research, September 11, 2014    Clinical Article

18 Incidence of needle tract seeding following prostate biopsy for suspected cancer - Review of the literature BJU International, June 30, 2014    Review Article

19 The impact of prostate cancer on men's everyday life European Journal of Cancer Care, September 16, 2014    Clinical Article

20 Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: Final analysis of a multicentre, open-label, early-access protocol trial The Lancet Oncology, September 25, 2014    Clinical Article

Indexed Journals in Urology: Urology, Journal of Urology, European Urology, The Prostatemore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close